[A19-35] Venetoclax (chronic lymphocytic leukaemia; combination with rituximab) - Addendum to Commission A18-81

Last updated 16.05.2019

Project no.:

Commission awarded on 09.04.2019 by the Federal Joint Committee (G-BA).

Report type:

Commission completed

Drug Assessment

Application field:


Adult patients with chronic lymphocytic leukaemia with at least one prior therapy and without 17p deletion and/or TP53 mutation who are candidates for chemoimmunotherapy

Result of dossier assessment:

Study MURANO: effects only in favour of venetoclax with rituximab in comparison with bendamustine with rituximab; derivation of an added benefit not possible due to deviation from appropriate comparator therapy, however


If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2019-05-16 A G-BA decision was published.

G-BA documents on this decision


Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.